Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...

AliveCor has received an additional FDA 510(k) clearance, this time for an algorithm that allows its smartphone ECG to detect atrial fibrillation -- an abnormal heart rhythm that isn't always ...

MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil ...

Smartphone-enabled heart monitor device maker AliveCor has launched a new app for patients, which is both timed with the new iOS 8 launch and incorporates the atrial fibrillation algorithm the company ...

- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral ...

Cardiac-focused digital health company iRhythm has received FDA 510(k) clearance for an algorithm that monitors atrial fibrillation and will be paired with wearable technology. The Zio ECG Utilization ...

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and ...